Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes

Hirulog therapy has been studied extensively in numerous settings including prevention of DVT, treatment of unstable angina, treatment of acute myocardial infarction during thrombolysis, and prevention of acute complications of PTCA. Being one of the first direct thrombin inhibitors in clinical deve...

Full description

Saved in:
Bibliographic Details
Published inCoronary artery disease Vol. 7; no. 6; p. 438
Main Authors Maraganore, J M, Adelman, B A
Format Journal Article
LanguageEnglish
Published England 01.06.1996
Subjects
Acute Disease
Antithrombins - therapeutic use
Coronary Disease - drug therapy
Hirudin Therapy
Hirudins - analogs & derivatives
Humans
Peptide Fragments - therapeutic use
Recombinant Proteins - therapeutic use
Syndrome
Thrombophlebitis - blood
Thrombophlebitis - prevention & control
Online AccessGet more information

Cover

More Information
Summary:Hirulog therapy has been studied extensively in numerous settings including prevention of DVT, treatment of unstable angina, treatment of acute myocardial infarction during thrombolysis, and prevention of acute complications of PTCA. Being one of the first direct thrombin inhibitors in clinical development, it has had to 'test the waters', so to speak, of the relationship between pathophysiology and clinical trial design: what are the correct indications, patient entry criteria, endopoints, frequency and duration of dosing, and so on? Our findings validate a role for thrombin in treating arterial thromboembolism and demonstrate clinical activity and tolerability of Hirulog.
ISSN:0954-6928
DOI:10.1097/00019501-199606000-00006